These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9655651

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
    Kim S, Iwao H.
    J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
    [Abstract] [Full Text] [Related]

  • 3. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Paull JR, Widdop RE.
    J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
    Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F.
    Blood Press Suppl; 1994 Aug; 5():54-6. PubMed ID: 7889201
    [Abstract] [Full Text] [Related]

  • 6. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y, Naka T.
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [Abstract] [Full Text] [Related]

  • 7. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
    Brown L, Duce B, Miric G, Sernia C.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats.
    Bennai F, Morsing P, Paliege A, Ketteler M, Mayer B, Tapp R, Bachmann S.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S104-15. PubMed ID: 9892150
    [Abstract] [Full Text] [Related]

  • 10. Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats.
    Sasamura H, Shimizu-Hirota R, Nakaya H, Saruta T.
    Hypertens Res; 2001 Mar; 24(2):165-72. PubMed ID: 11325076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
    Kim S, Zhan Y, Izumi Y, Iwao H.
    Hypertension; 2000 Mar; 35(3):769-74. PubMed ID: 10720593
    [Abstract] [Full Text] [Related]

  • 14. Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats.
    Nagura J, Yamamoto M, Hui C, Yasuda S, Hachisu M, Konno F.
    Clin Exp Pharmacol Physiol; 1996 Mar; 23(3):229-35. PubMed ID: 8934613
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
    Fujita H, Takeda K, Miki S, Morimoto S, Kawa T, Uchida A, Itoh H, Nakata T, Sasaki S, Nakagawa M.
    Hypertens Res; 1997 Dec; 20(4):263-7. PubMed ID: 9453261
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.